Halozyme price target raised to $53 from $52 at Piper Sandler
Piper Sandler raised the firm’s price target on Halozyme (HALO) to $53 from $52 and keeps a Neutral rating on the shares after maintaining FY24 ...
Hosted on MSN1d
Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock?
Investors in Halozyme Therapeutics, Inc. HALO need to pay close attention to the stock based on moves in the options market lately. That is because the March 21, 2025 $25.00 Call had some of the ...
Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025
Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...
Piper Sandler Remains a Hold on Halozyme (HALO)
In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on Halozyme (HALO – Research Report), with a price ...
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...
bovnews1d
Halozyme Therapeutics, Inc. (HALO) Stock Settles at $53.76: What’s Contributing to This Price Point?
Wells Fargo has recently reduced Halozyme Therapeutics, Inc. (HALO) stock to Equal Weight rating, as announced on October 7, 2024, according to Finviz. Earlier, on September 19, 2024, JP Morgan had ...
Halozyme: Recent Approvals Alter My Appetite
Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's ...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Morningstar11d
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co ...
Zacks.com on MSN3d
Zacks.com featured highlights include Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical
Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical are part of the Zacks Screen of the Week article.